BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 16186594)

  • 21. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
    Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
    Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
    Yildiz F; Zengin N; Engin H; Güllü I; Barista I; Caglar M; Ozyar E; Cengiz M; Gürkaynak M; Zorlu F; Caner B; Atahan IL; Tekuzman G
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):839-46. PubMed ID: 15465201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma.
    Al-Jizani WA; Al-Mansour MM; Al-Fayea TM; Shafi RU; Kazkaz GA; Bayer AM; Al-Foheidi ME; Ibrahim EM
    Future Oncol; 2015; 11(15):2149-57. PubMed ID: 26235180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
    Campbell BA; Voss N; Pickles T; Morris J; Gascoyne RD; Savage KJ; Connors JM
    J Clin Oncol; 2008 Nov; 26(32):5170-4. PubMed ID: 18838714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
    J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.
    Taparra K; Liu H; Polley MY; Ristow K; Habermann TM; Ansell SM
    Leuk Lymphoma; 2020 Feb; 61(2):298-308. PubMed ID: 31517559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
    Diehl V; Fuchs M;
    Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
    Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
    Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
    Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M;
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group.
    Klimm B; Franklin J; Stein H; Eichenauer DA; Haverkamp H; Diehl V; Fuchs M; Borchmann P; Engert A
    J Clin Oncol; 2011 Oct; 29(29):3914-20. PubMed ID: 21911729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
    Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
    Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents.
    Jones GL; Taylor PR; Windebank KP; Hoye NA; Lucraft H; Wood K; Angus B; Proctor SJ
    Br J Cancer; 2007 Jul; 97(1):29-36. PubMed ID: 17533403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
    Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P
    J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma.
    Koh ES; Sun A; Tran TH; Tsang R; Pintilie M; Hodgson DC; Wells W; Heaton R; Gospodarowicz MK
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):223-8. PubMed ID: 16904523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity.
    Friedberg JW; Neuberg D; Kim H; Miyata S; McCauley M; Fisher DC; Takvorian T; Canellos GP
    Cancer; 2003 Sep; 98(5):978-82. PubMed ID: 12942565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era.
    Moccia AA; Donaldson J; Chhanabhai M; Hoskins PJ; Klasa RJ; Savage KJ; Shenkier TN; Slack GW; Skinnider B; Gascoyne RD; Connors JM; Sehn LH
    J Clin Oncol; 2012 Sep; 30(27):3383-8. PubMed ID: 22869887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
    Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
    J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi.
    Gobbi PG; Broglia C; Merli F; Dell'Olio M; Stelitano C; Iannitto E; Federico M; Bertè R; Luisi D; Molica S; Cavalli C; Dezza L; Ascari E
    Cancer; 2003 Dec; 98(11):2393-401. PubMed ID: 14635074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?
    Abou Yehia Z; Mikhaeel GN; Smith G; Pinnix CC; Milgrom SA; Tang C; Jiang W; Fanale MA; Oki Y; Shank JH; Horace T; Reddy J; Akhtari M; Gunther JR; Suki T; Allen PK; Turner S; Mawlawi O; Dabaja BS
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):951-958. PubMed ID: 27742539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
    Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
    Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.